Employees: 1,659
Size Zhejiang Gongdong Medical Technology (605369.SS) is a China Health Care company (Medical Specialties) with a market value of $542M, the 3495th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥16.69 on 18 Nov 2026.
Performance Over six months the shares fell 20.9%, against -19.9% for the median peer and -20.0% for the China market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 5.8% over the last twelve months (peer median +7.8%); the operating margin is 8.5% (peer median 2.2%).
Valuation It trades at 23.5× forward earnings against a peer median of 20.4× (4th most expensive of 9).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.8 points above its cost of capital (8.9% WACC).
Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.19B | CN¥1.13B | CN¥1.11B | CN¥964M | CN¥1.46B |
| Revenue growth | — | +2% | +15% | -34% | — |
| Gross profit | CN¥409M | CN¥302M | CN¥348M | CN¥297M | CN¥559M |
| EBITDA | n/a | CN¥199M | CN¥249M | CN¥194M | CN¥365M |
| Net income | CN¥71.5M | CN¥51.5M | CN¥172M | CN¥109M | CN¥326M |
| Free cash flow | CN¥192M | CN¥142M | CN¥108M | CN¥63.7M | CN¥113M |
| Capital expenditure | CN¥133M | CN¥112M | CN¥110M | CN¥122M | CN¥172M |
| Total debt | CN¥177M | CN¥179M | CN¥52.5M | CN¥44.9M | CN¥21.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 605369.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.7% | -5.8% | 10th lowest of 21 |
| 6-month return | -20.9% | -19.9% | 11th highest of 21 |
| Distance from 52-week high | -26.4% | -41.7% | 6th highest of 21 |
| Revenue growth (TTM) | +5.8% | +7.8% | 9th lowest of 21 |
| Operating margin | 8.5% | 2.2% | 7th highest of 21 |
| Forward P/E | 23.5× | 20.4× | 4th most expensive of 9 |
| Growth the price implies (Req g, 7 yrs) | 10.2% | 8.4% | 4th most demanding of 8 |
| Growth delivered (Del g) | +6.5% | -7.7% | 3rd highest of 8 |
| Hurdle (Req g minus delivered) | +3.7 pp | +13.8 pp | 3rd least demanding of 8 |
| ROIC minus cost of capital | +1.8 pp | -3.3 pp | 5th highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Gongdong Medical Technology 605369.SS | China | $542M | -21% | +6% | 9% | 23.5× | 10.2% | +6.5% |
| Contec Medical Systems 300869.SZ | China | $547M | -26% | -2% | -16% | n/a | 15.0% | -19.8% |
| Jin Medical International ZJYL | United States | $532M | +47% | -14% | 2% | n/a | n/a | n/a |
| Myriad Genetics MYGN | United States | $530M | +45% | -3% | -13% | n/a | n/a | n/a |
| AVITA Medical RCEL | United States | $529M | +290% | +17% | -34% | n/a | n/a | n/a |
| Cowealth Medical China 603122.SS | China | $562M | -34% | -18% | -5% | n/a | n/a | n/a |
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $563M | -57% | +28% | 7% | 33.7× | n/a | n/a |
| MedicalSystem Biotechnology 300439.SZ | China | $518M | -9% | +14% | 2% | n/a | 6.0% | -7.7% |
| Anbio Biotechnology NNNN | United States | $518M | -89% | +10% | 67% | n/a | n/a | n/a |
| Pacific Biosciences of California PACB | United States | $573M | +54% | +4% | -98% | n/a | n/a | n/a |
| Guangdong Hybribio Biotech 300639.SZ | China | $511M | -18% | -7% | 4% | 57.3× | 0.4% | -13.2% |
| Jiangsu Hanvo Safety Product 300952.SZ | China | $575M | -38% | +6% | 8% | 39.7× | n/a | n/a |
| Shofu 7979.T | Japan | $510M | +32% | +9% | 14% | 13.2× | n/a | n/a |
| Anteris Technologies Global AVR | United States | $508M | -40% | +9% | -4,880% | n/a | n/a | n/a |
| Assure Tech (Hangzhou) 688075.SS | China | $508M | -27% | -9% | -8% | n/a | 30.8% | -18.6% |
| Orchestra BioMed OBIO | United States | $587M | +87% | +1,007% | -195% | n/a | n/a | n/a |
| Zhejiang Orient Gene Biotech 688298.SS | China | $500M | -27% | +18% | -60% | n/a | n/a | n/a |
| Nanjing Vishee Medical Technology 688580.SS | China | $499M | -43% | +7% | 24% | 19.7× | 20.1% | +4.2% |
| Ningbo David Medical Device 300314.SZ | China | $589M | +25% | +19% | 11% | 12.0× | n/a | n/a |
| Hangzhou AGS MedTech 688581.SS | China | $590M | -22% | -18% | 33% | 18.9× | 0.4% | +27.8% |
| Tactile Systems Technology TCMD | United States | $592M | +6% | +14% | 9% | 21.1× | 8.4% | +12.0% |